Editorials

Testing times for HIV

BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f5556 (Published 18 September 2013) Cite this as: BMJ 2013;347:f5556

This article has a correction. Please see:

  1. Jonathan Weber, vice dean (research),
  2. Roger Tatoud, senior programme manager
  1. 1Wright-Fleming Institute, Faculty of Medicine, Imperial College London W2 1PG, UK
  1. j.weber{at}imperial.ac.uk

Multiple strategies are needed to reach the HIV infected, undiagnosed population

Vaccines are key instruments of public health through which infectious diseases are controlled, but no vaccine is yet on the horizon to prevent HIV infection and control the epidemic, now in its fourth decade. So other, less tried, routes need to be pursued. There is a single example in global public health of the elimination of an infectious disease at a continental level without a vaccine—that of the control of the endemic trepanematoses (yaws, bejel, and pinta) through active case finding and widespread use of benzathine penicillin.1 For antiretroviral therapy to be similarly successful, ever larger proportions of the HIV positive population will need to be identified. This relies on enhanced HIV testing, and in a linked article (doi:10.1136/bmj.f5086), Read and colleagues investigate whether the provision of home HIV testing to men who have sex with men attending a health service would increase their frequency of HIV testing over time.2

Antiretroviral therapy, which has transformed the lives of HIV infected patients, is now the focus of intense investigation as a preventive agent, with strategies for both infected and uninfected populations. But can antiretroviral therapy control the HIV epidemic …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe